NRx wins first FDA drug approval, launches ketamine sales and targets profitability in 2027
- NRx now estimates the ketamine market at about $400 million, down from $750 million cited on prior calls.
- SPARC-TMS enrollment is delayed until 2027; $11.2M DARPA contract met initial milestones, with first Q4 invoices approved.
- Fiscal Q3 2026 non-GAAP EPS of $-0.05 beat estimates, while $1.2M revenue missed, up from $0.2M in Q3 2025.
- Net loss narrowed to $2.2M, or $0.05 per share, from $5.9M YoY.
- FDA approved preservative-free IV ketamine in novel blow-fill-seal packaging on October 29.
- Seventeen-person sales force launched; first commercial ketamine order arrived shortly after quarter-end.
- Cash increased to $19.8M with no convertible debt remaining after equity raise.
- Company reorganized into four divisions, each targeting non-dilutive funding and standalone profitability.
- NRX-100 rolling NDA planned by year-end, with 2027 depression approval sought via regular or accelerated paths.
- Hope Therapeutics runs six Florida clinics, expanding TMS capabilities and driving higher service revenue.
- GeNeuro ALS and schizophrenia antibody programs viewed as major upside, with external funding targeted to limit dilution.
- Main concern: Execution and regulatory risk across multiple programs while long-term funding still depends on external capital.
- NRX-200 subcutaneous ketamine program announced alongside fiscal third-quarter results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.